Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis - Establishing disease prognosis and monitoring patients

Nature Reviews Neurology

Volumn 11, Issue 10, 2015, Pages 597-606

  Wattjes, Mike P ^a   Rovira, Àlex ^b   Miller, David ^b,c   Yousry, Tarek A ^d   Sormani, Maria P ^e,f   De Stefano, Nicola ^g   Tintoré, Mar ^b   Auger, Cristina ^b   Tur, Carmen ^b   Filippi, Massimo ^h   Rocca, Maria A ^h   Fazekas, Franz ⁱ   Kappos, Ludwig ^j   Polman, Chris ^a   Barkhof, Frederik ^a   Montalban, Xavier ^b  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c Queen Square MS Centre   (United Kingdom)

^d NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

^f UNIVERSITY OF GENOA   (Italy)

^g UNIVERSITY OF SIENA   (Italy)

^h SAN RAFFAELE HOSPITAL   (Italy)

ⁱ MEDICAL UNIVERSITY OF GRAZ   (Austria)

^j UNIVERSITY OF BASEL   (Switzerland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; FINGOLIMOD; FUMARIC ACID DIMETHYL ESTER; GADOLINIUM; NATALIZUMAB; RITUXIMAB;

ARTICLE; BLOOD BRAIN BARRIER; BRAIN SIZE; CLINICAL PRACTICE; COMORBIDITY; CONSENSUS DEVELOPMENT; CONTRAST ENHANCEMENT; DEMYELINATING DISEASE; DEMYELINATION; DIAGNOSTIC TEST ACCURACY STUDY; DIFFERENTIAL DIAGNOSIS; DIFFUSION TENSOR IMAGING; DISEASE ACTIVITY; DISEASE COURSE; DRUG SURVEILLANCE PROGRAM; ENCEPHALITIS; EXPANDED DISABILITY STATUS SCALE; FRACTIONAL ANISOTROPY; HERPES ZOSTER ENCEPHALITIS; HUMAN; IMAGE ANALYSIS; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; MEDICAL SOCIETY; MULTIPLE SCLEROSIS; NERVE DEGENERATION; NUCLEAR MAGNETIC RESONANCE IMAGING; OPPORTUNISTIC INFECTION; PATIENT MONITORING; PRACTICE GUIDELINE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PROTON NUCLEAR MAGNETIC RESONANCE; PUBLICATION; QUANTITATIVE ANALYSIS; RELAPSE; SENSITIVITY AND SPECIFICITY; STANDARDIZATION; TREATMENT RESPONSE; BRAIN; CONSENSUS; DRUG EFFECTS; EVIDENCE BASED MEDICINE; IMMUNOTHERAPY; PATHOLOGY; PROCEDURES;

BRAIN; CONSENSUS; DISEASE PROGRESSION; EVIDENCE-BASED MEDICINE; HUMANS; IMMUNOTHERAPY; MAGNETIC RESONANCE IMAGING; MULTIPLE SCLEROSIS; PROGNOSIS;

EID: 84942991168     PISSN: 17594758     EISSN: 17594766     Source Type: Journal    
DOI: 10.1038/nrneurol.2015.157     Document Type: Article

References (134)

1. Fazekas, F. et al. The contribution of magnetic resonance imaging to the diagnosis of multiple sclerosis. Neurology 53, 448-456 (1999).
2. Miller, D. H. et al. Role of magnetic resonance imaging within diagnostic criteria for multiple sclerosis. Ann. Neurol. 56, 273-278 (2004).
3. Charil, A. et al. MRI and the diagnosis of multiple sclerosis: expanding the concept of "no better explanation". Lancet Neurol. 5, 841-852 (2006).
4. McDonald, W. I. et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann. Neurol. 50, 121-127 (2001).
5. Polman, C. H. et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann. Neurol. 58, 840-846 (2005).
6. Polman, C. H. et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann. Neurol. 69, 292-302 (2011).
7. Rommer, P. S. et al. Requirement for safety monitoring for approved multiple sclerosis therapies: an overview. Clin. Exp. Immunol. 175, 397-407 (2014).
8. Cross, A. H. & Naismith, R. T. Established and novel disease-modifying treatments in multiple sclerosis. J. Intern. Med. 275, 350-363 (2014).
9. Tran, J. Q. et al. Randomized phase I trials of the safety/tolerability of anti-LINGO-1 monoclonal antibody BIIB033. Neurol. Neuroimmunol. Neuroinflamm. 1, e18 (2014).
10. Rovira, A. et al. MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis-clinical implementation in the diagnostic process. Nat. Rev. Neurol. 11, 471-482 (2015).
11. Barkhof, F. The clinico-radiological paradox in multiple sclerosis revisited. Curr. Opin. Neurol. 15, 239-245 (2002).
12. Tintore, M. et al. Defining high, medium and low impact prognostic factors for developing multiple sclerosis. Brain 138, 1863-1874 (2015).
13. Fisniku, L. K. et al. Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain 131, 808-817 (2008).
14. Swanton, J. K. et al. Early MRI in optic neuritis: the risk for clinically definite multiple sclerosis. Mult. Scler. 16, 156-165 (2010).
15. Tintore, M. et al. Brainstem lesions in clinically isolated syndromes. Neurology 75, 1933-1938 (2010).
16. Swanton, J. K. et al. Early MRI in optic neuritis: the risk for disability. Neurology 72, 542-550 (2009).
17. Minneboo, A. et al. Infratentorial lesions predict long-term disability in patients with initial findings suggestive of multiple sclerosis. Arch. Neurol. 61, 217-221 (2004).
18. Simon, J. H. et al. Standardized MR imaging protocol for multiple sclerosis: Consortium of MS Centers consensus guidelines. AJNR Am. J. Neuroradiol. 27, 455-461 (2006).
19. Cook, S. D. et al. Use of magnetic resonance imaging as well as clinical disease activity in the clinical classification of multiple sclerosis and assessment of its course: a report from an international CMSC Consensus Conference, March 5-7, 2010. Int. J. MS Care 14, 105-114 (2012).
20. Verhey, L. H., Narayanan, S. & Banwell, B. Standardized magnetic resonance imaging acquisition and reporting in pediatric multiple sclerosis. Neuroimaging Clin. N. Am. 23, 17-26 (2013).
21. Thorpe, J. W. et al. Serial gadolinium-enhanced MRI of the brain and spinal cord in early relapsing-remitting multiple sclerosis. Neurology 46, 373-378 (1996).
22. Silver, N. C. et al. A modified protocol to improve the detection of enhancing brain and spinal cord lesions in multiple sclerosis. J. Neurol. 248, 215-224 (2001).
23. Lycklama, G. et al. Spinal-cord MRI in multiple sclerosis. Lancet Neurol. 2, 555-562 (2003).
24. Sormani, M. P. et al. Magnetic resonance active lesions as individual-level surrogate for relapses in multiple sclerosis. Mult. Scler. 17, 541-549 (2011).
25. Barkhof, F. et al. MRI monitoring of immunomodulation in relapse-onset multiple sclerosis trials. Nat. Rev. Neurol. 8, 13-21 (2011).
26. Barkhof, F., Calabresi, P. A., Miller, D. H. & Reingold, S. C. Imaging outcomes for neuroprotection and repair in multiple sclerosis trials. Imaging outcomes for neuroprotection and repair in multiple sclerosis trials. Nat. Rev. Neurol. 5, 256-266 (2009).
27. Nagtegaal, G. J. et al. Interferon beta-1b reduces black holes in a randomised trial of clinically isolated syndrome. Mult. Scler. 20, 234-242 (2014).
28. Mitjana, R. et al. Diagnostic value of brain chronic black holes on T1-weighted MR images in clinically isolated syndromes. Mult. Scler. 20, 1471-1477 (2014).
29. Giorgio, A. et al. Relevance of hypointense brain MRI lesions for long-term worsening of clinical disability in relapsing multiple sclerosis. Mult. Scler. 20, 214-219 (2014).
30. Curtin, F. & Hartung, H. P. Novel therapeutic options for multiple sclerosis. Expert Rev. Clin. Pharmacol. 7, 91-104 (2014).
31. Mallik, S., Samson, R. S., Wheeler-Kingshott, C. A. & Miller, D. H. Imaging outcomes for trials of remyelination in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 85, 1396-1404 (2014).
32. De Stefano, N. et al. Clinical relevance of brain volume measures in multiple sclerosis. CNS Drugs 28, 147-156 (2014).
33. De Stefano, N. et al. Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes. Neurology 74, 1868-1876 (2010).
34. Fisher, E., Lee, J. C., Nakamura, K. & Rudick, R. A. Gray matter atrophy in multiple sclerosis: a longitudinal study. Ann. Neurol. 64, 255-265 (2008).
35. Popescu, V. et al. Brain atrophy and lesion load predict long term disability in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 84, 1082-1091 (2013).
36. Filippi, M. et al. Gray matter damage predicts the accumulation of disability 13 years later in MS. Neurology 81, 1759-1767 (2013).
37. Lavorgna, L. et al. Clinical and magnetic resonance imaging predictors of disease progression in multiple sclerosis: a nine-year follow-up study. Mult. Scler. 20, 220-226 (2014).
38. Gobbi, C. et al. Influence of the topography of brain damage on depression and fatigue in patients with multiple sclerosis. Mult. Scler. 20, 192-201 (2014).
39. Fisher, E. et al. Relationship between brain atrophy and disability: an 8.year follow-up study of multiple sclerosis patients. Mult. Scler. 6, 373-377 (2000).
40. Shiee, N. et al. Revisiting brain atrophy and its relationship to disability in multiple sclerosis. PLoS ONE 7, e37049 (2012).
41. Jacobsen, C. et al. Brain atrophy and disability progression in multiple sclerosis patients: a 10-year follow-up study. J. Neurol. Neurosurg. Psychiatry 85, 1109-1115 (2014).
42. Filippi, M. et al. Association between pathological and MRI findings in multiple sclerosis. Lancet Neurol. 11, 349-360 (2012).
43. Sormani, M. P., Arnold, D. L. & De Stefano, N. Treatment effect on brain atrophy correlates with treatment effect on disability in multiple sclerosis. Ann. Neurol. 75, 43-49 (2014).
44. Zivadinov, R. et al. Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis. Neurology 71, 136-144 (2008).
45. Vidal-Jordana, A. et al. Early brain pseudoatrophy while on natalizumab therapy is due to white matter volume changes. Mult. Scler. 19, 1175-1181 (2013).
46. Sastre-Garriga, J. et al. Brain atrophy in natalizumab-treated patients: a 3.year follow-up. Mult. Scler. 21, 749-756 (2015).
47. De Stefano, N. & Arnold, D. L. Towards a better understanding of pseudoatrophy in the brain of multiple sclerosis patients. Mult. Scler. 21, 675-676 (2015).
48. Enzinger, C. et al. Risk factors for progression of brain atrophy in aging: six-year follow-up of normal subjects. Neurology 64, 1704-1711 (2005).
49. Huppertz, H. J., Kroll-Seger, J., Kloppel, S., Ganz, R. E. & Kassubek, J. Intra- and interscanner variability of automated voxel-based volumetry based on a 3D probabilistic atlas of human cerebral structures. Neuroimage 49, 2216-2224 (2010).
50. Ropele, S. & Fazekas, F. Magnetization transfer MR imaging in multiple sclerosis. Neuroimaging Clin. N. Am. 19, 27-36 (2009).
51. Rovaris, M., Agosta, F., Pagani, E. & Filippi, M. Diffusion tensor MR imaging. Neuroimaging Clin. N. Am. 19, 37-43 (2009).
52. van Waesberghe, J. H. et al. Axonal loss in multiple sclerosis lesions: magnetic resonance imaging insights into substrates of disability. Ann. Neurol. 46, 747-754 (1999).
53. Schmierer, K., Scaravilli, F., Altmann, D. R., Barker, G. J. & Miller, D. H. Magnetization transfer ratio and myelin in postmortem multiple sclerosis brain. Ann. Neurol. 56, 407-415 (2004).
54. Mottershead, J. P. et al. High field MRI correlates of myelin content and axonal density in multiple sclerosis-.a post-mortem study of the spinal cord. J. Neurol. 250, 1293-1301 (2003).
55. Sajja, B. R., Wolinsky, J. S. & Narayana, P. A. Proton magnetic resonance spectroscopy in multiple sclerosis. Neuroimaging Clin. N. Am. 19, 45-58 (2009).
56. Langkammer, C. et al. Quantitative MR imaging of brain iron: a postmortem validation study. Radiology 257, 455-462 (2010).
57. Filippi, M. & Rocca, M. A. New magnetic resonance imaging biomarkers for the diagnosis of multiple sclerosis. Expert Opin. Med. Diagn. 6, 109-120 (2012).
58. Filippi, M., Absinta, M. & Rocca, M. A. Future MRI tools in multiple sclerosis. J. Neurol. Sci. 331, 14-18 (2013).
59. Inglese, M. et al. The effect of interferon β-1b on quantities derived from MT MRI in secondary progressive MS. Neurology 60, 853-860 (2003).
60. Filippi, M. et al. European study on intravenous immunoglobulin in multiple sclerosis: results of magnetization transfer magnetic resonance imaging analysis. Arch. Neurol. 61, 1409-1412 (2004).
61. Narayanan, S. et al. Axonal metabolic recovery in multiple sclerosis patients treated with interferon beta-1b. J. Neurol. 248, 979-986 (2001).
62. Sajja, B. R., Narayana, P. A., Wolinsky, J. S. & Ahn, C. W. Longitudinal magnetic resonance spectroscopic imaging of primary progressive multiple sclerosis patients treated with glatiramer acetate: multicenter study. Mult. Scler. 14, 73-80 (2008).
63. Chen, J. T., Collins, D. L., Atkins, H. L., Freedman, M. S. & Arnold, D. L. Magnetization transfer ratio evolution with demyelination and remyelination in multiple sclerosis lesions. Ann. Neurol. 63, 254-262 (2008).
64. Button, T. et al. Magnetization transfer imaging in multiple sclerosis treated with alemtuzumab. Mult. Scler. 19, 241-244 (2012).
65. Filippi, M. et al. Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damage. J. Neurol. Neurosurg. Psychiatry 85, 851-858 (2014).
66. Rio, J. et al. Defining the response to interferon-β in relapsing.remitting multiple sclerosis patients. Ann. Neurol. 59, 344-352 (2006).
67. Rio, J. et al. Measures in the first year of therapy predict the response to interferon β in MS. Mult. Scler. 15, 848-853 (2009).
68. Rio, J., Comabella, M. & Montalban, X. Predicting responders to therapies for multiple sclerosis. Nat. Rev. Neurol. 5, 553-560 (2009).
69. Rudick, R. A., Lee, J. C., Simon, J., Ransohoff, R. M. & Fisher, E. Defining interferon β response status in multiple sclerosis patients. Ann. Neurol. 56, 548-555 (2004).
70. Healy, B. C. et al. A method for evaluating treatment switching criteria in multiple sclerosis. Mult. Scler. 16, 1483-1489 (2010).
71. Barkhof, F. et al. Validation of diagnostic magnetic resonance imaging criteria for multiple sclerosis and response to interferon β1a. Ann. Neurol. 53, 718-724 (2003).
72. Kappos, L. et al. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing.remitting MS. Neurology 67, 944-953 (2006).
73. Romeo, M. et al. Clinical and MRI predictors of response to interferon-beta and glatiramer acetate in relapsing.remitting multiple sclerosis patients. Eur. J. Neurol. 20, 1060-1067 (2013).
74. Signori, A., Schiavetti, I., Gallo, F. & Sormani, M. P. Subgroups of multiple sclerosis patients with larger treatment benefits: a meta-analysis of randomized trials. Eur. J. Neurol. 22, 960-966 (2015).
75. Perez-Miralles, F. et al. Clinical impact of early brain atrophy in clinically isolated syndromes. Mult. Scler. 19, 1878-1886 (2013).
76. Fisher, E. et al. Eight-year follow-up study of brain atrophy in patients with MS. Neurology 59, 1412-1420 (2002).
77. Sombekke, M. H. et al. Spinal cord lesions in patients with clinically isolated syndrome: a powerful tool in diagnosis and prognosis. Neurology 80, 69-75 (2013).
78. Sormani, M. P. & De Stefano, N. Defining and scoring response to IFN.β in multiple sclerosis. Nat. Rev. Neurol. 9, 504-512 (2013).
79. Sormani, M. P. et al. Scoring treatment response in patients with relapsing multiple sclerosis. Mult. Scler. 19, 605-612 (2013).
80. Prosperini, L. et al. Interferon beta failure predicted by EMA criteria or isolated MRI activity in multiple sclerosis. Mult. Scler. 20, 566-576 (2014).
81. Freedman, M. S. et al. Treatment optimization in MS: Canadian MS Working Group updated recommendations. Can. J. Neurol. Sci. 40, 307-323 (2013).
82. Stangel, M., Penner, I. K., Kallmann, B. A., Lukas, C. & Kieseier, B. C. Towards the implementation of ?eno evidence of disease activity?f in multiple sclerosis treatment: the multiple sclerosis decision model. Ther. Adv. Neurol. Disord. 8, 3-13 (2014).
83. Dhib-Jalbut, S. Mechanisms of action of interferons and glatiramer acetate in multiple sclerosis. Neurology 58 (8 Suppl. 4), S3.S9 (2002).
84. Comi, G., Filippi, M. & Wolinsky, J. S. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging.measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group. Ann. Neurol. 49, 290-297 (2001).
85. Rio, J. et al. Evaluating the response to glatiramer acetate in relapsing.remitting multiple sclerosis (RRMS) patients. Mult. Scler. 20, 1602-1608 (2014).
86. Filippi, M. et al. Guidelines from the Italian Neurological and Neuroradiological Societies for the use of magnetic resonance imaging in daily life clinical practice of multiple sclerosis patients. Neurol. Sci. 34, 2085-2093 (2013).
87. Miller, D. H., Barkhof, F. & Nauta, J. J. Gadolinium enhancement increases the sensitivity of MRI in detecting disease activity in multiple sclerosis. Brain 116, 1077-1094 (1993).
88. Cotton, F., Weiner, H. L., Jolesz, F. A. & Guttmann, C. R. MRI contrast uptake in new lesions in relapsing.remitting MS followed at weekly intervals. Neurology 60, 640-646 (2003).
89. Erbayat Altay, E. et al. Reliability of classifying multiple sclerosis disease activity using magnetic resonance imaging in a multiple sclerosis clinic. JAMA Neurol. 70, 338-344 (2013).
90. Moraal, B. et al. Improved detection of active multiple sclerosis lesions: 3D subtraction imaging. Radiology 255, 154-163 (2010).
91. Moraal, B. et al. Long-interval T2-weighted subtraction magnetic resonance imaging: a powerful new outcome measure in multiple sclerosis trials. Ann. Neurol. 67, 667-675 (2010).
92. Battaglini, M. et al. Automated identification of brain new lesions in multiple sclerosis using subtraction images. J. Magn. Reson. Imaging 39, 1543-1549 (2014).
93. Weber, M. S. et al. Current treatment strategies for multiple sclerosis.efficacy versus neurological adverse effects. Curr. Pharm. Des. 18, 209-219 (2012).
94. Kappos, L. et al. Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring. Lancet Neurol. 10, 745-758 (2011).
95. Yousry, T. A. et al. MRI pattern in natalizumab-associated progressive multifocal leukoencephalopathy. Ann. Neurol. 72, 779-787 (2012).
96. Wattjes, M. P. et al. The chameleon of neuroinflammation: magnetic resonance imaging characteristics of natalizumab-associated progressive multifocal leukoencephalopathy. Mult. Scler. 19, 1826-1840 (2013).
97. Wattjes, M. P. & Barkhof, F. Diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy using MRI. Curr. Opin. Neurol. 27, 260-270 (2014).
98. Wattjes, M. P. et al. MRI pattern in asymptomatic natalizumab-associated PML. J. Neurol. Neurosurg. Psychiatry 86, 793-798 (2015).
99. Dong-Si, T. et al. Outcome and survival of asymptomatic PML in natalizumab-treated MS patients. Ann. Clin. Transl. Neurol. 1, 755-764 (2014).
100. Sorensen, P. S. et al. Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab. Mult. Scler. 18, 143-152 (2012).
101. Bloomgren, G. et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N. Engl. J. Med. 366, 1870-1880 (2012).
102. Warnke, C. et al. Changes to anti-JCV antibody levels in a Swedish national MS cohort. J. Neurol. Neurosurg. Psychiatry 84, 1199-1205 (2013).
103. Plavina T. et al. Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy. Ann. Neurol. 76, 802-812 (2014).
104. Richert, N. et al. Imaging findings for PML in natalizumab-treated MS patients [oral 99]. Mult. Scler. 18 (Suppl. 4): 27-28 (2012).
105. Gheuens, S. et al. Simultaneous PML-IRIS after discontinuation of natalizumab in a patient with MS. Neurology 78, 1390-1393 (2012).
106. Waggoner, J., Martinu, T. & Palmer, S. M. Progressive multifocal leukoencephalopathy following heightened immunosuppression after lung transplant. J. Heart Lung Transplant. 28, 395-398 (2009).
107. Clifford, D. B. et al. Rituximab-associated progressive multifocal leukoencephalopathy in rheumatoid arthritis. Arch. Neurol. 68, 1156-1164 (2011).
108. van Oosten, B. W., Killestein, J., Barkhof, F., Polman, C. H. & Wattjes, M. P. PML in a patient treated with dimethyl fumarate from a compounding pharmacy. N. Engl. J. Med. 368, 1658-1659 (2013).
109. Rosenkranz, T., Novas, M. & Terborg, C. PML in a patient with lymphocytopenia treated with dimethyl fumarate. N. Engl. J. Med. 372, 1476-1478 (2015).
110. Nieuwkamp, D. J. et al. PML in a patient without severe lymphocytopenia receiving dimethyl fumarate. N. Engl. J. Med. 372, 1474-1476 (2015).
111. Gross, C. M., Baumgartner, A., Rauer, S. & Stich, O. Multiple sclerosis rebound following herpes zoster infection and suspension of fingolimod. Neurology 79, 2006-2007 (2012).
112. Ratchford, J. N., Costello, K., Reich, D. S. & Calabresi, P. A. Varicella-zoster virus encephalitis and vasculopathy in a patient treated with fingolimod. Neurology 79, 2002-2004 (2012).
113. Leypoldt, F. et al. Hemorrhaging focal encephalitis under fingolimod (FTY720) treatment: a case report. Neurology 72, 1022-1024 (2009).
114. Arvin, A. M. et al. Varicella-zoster virus infections in patients treated with fingolimod: risk assessment and consensus recommendations for management. JAMA Neurol. 72, 31-39 (2015).
115. Visser, F., Wattjes, M. P., Pouwels, P. J., Linssen, W. H. & van Oosten, B. W. Tumefactive multiple sclerosis lesions under fingolimod treatment. Neurology 79, 2000-2003 (2012).
116. Pilz, G. et al. Tumefactive MS lesions under fingolimod: a case report and literature review. Neurology 81, 1654-1658 (2013).
117. Fine, A. J., Sorbello, A., Kortepeter, C. & Scarazzini, L. Progressive multifocal leukoencephalopathy after natalizumab discontinuation. Ann. Neurol. 75, 108-115 (2014).
118. Wattjes, M. P. & Killestein, J. Progressive multifocal leukoencephalopathy after natalizumab discontinuation: few and true? Ann. Neurol. 75, 462 (2014).
119. Killestein, J. et al. PML-IRIS during fingolimod diagnosed after natalizumab discontinuation. Case Rep. Neurol. Med. 2014, 307872 (2014).
120. Franklin, R. J., French-Constant, C., Edgar, J. M. & Smith, K. J. Neuroprotection and repair in multiple sclerosis. Nat. Rev. Neurol. 8, 624-634 (2012).
121. Geurts, J. J. & Barkhof, F. Grey matter pathology in multiple sclerosis. Lancet Neurol. 7, 841-851 (2008).
122. Calabrese, M., Rinaldi, F., Grossi, P. & Gallo, P. Cortical pathology and cognitive impairment in multiple sclerosis. Expert Rev. Neurother. 11, 425-432 (2011).
123. Calabrese, M. et al. Cortical lesion load associates with progression of disability in multiple sclerosis. Brain 135, 2952-2961 (2012).
124. Muhlert, N. et al. The grey matter correlates of impaired decision-making in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 86, 530-536 (2015).
125. Roosendaal, S. D. et al. Accumulation of cortical lesions in MS: relation with cognitive impairment. Mult. Scler. 15, 708-714 (2009).
126. Nelson, F. et al. Intracortical lesions by 3 T magnetic resonance imaging and correlation with cognitive impairment in multiple sclerosis. Mult. Scler. 17, 1122-1129 (2011).
127. Simon, B. et al. Improved in vivo detection of cortical lesions in multiple sclerosis using double inversion recovery MR imaging at 3 Tesla. Eur. Radiol. 20, 1675-1683 (2010).
128. Sethi, V. et al., Improved detection of cortical MS lesions with phase-sensitive inversion recovery MRI. J. Neurol. Neurosurg. Psychiatry 83, 877-882 (2012).
129. Geurts, J. J. et al. Consensus recommendations for MS cortical lesion scoring using double inversion recovery MRI. Neurology 76, 418-424 (2011).
130. Daams, M. et al. Mean upper cervical cord area (MUCCA) measurement in long-standing multiple sclerosis: relation to brain findings and clinical disability. Mult. Scler. 20, 1860-1865 (2014).
131. Filippi, M. et al. Ultra-high-field MR imaging in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 85, 60-66 (2014).
132. Kilsdonk, I. D., Wattjes, M. P. & Geurts, J. J. Ultra-high field MRI: looking through the ?emacroscope?f. J. Neurol. Neurosurg. Psychiatry 85, 4 (2014).
133. Kilsdonk, I. D., de Graaf, W. L., Barkhof, F. & Wattjes, M. P. Inflammation high-field magnetic resonance imaging. Neuroimaging Clin. N. Am. 22, 135-157 (2012).
134. Rio, J. et al. Relationship between MRI lesion activity and response to IFN.β in relapsing.remitting multiple sclerosis patients. Mult. Scler. 14, 479-484 (2008).